ArticleOncotarget2012
MiR-181b: new perspective to evaluate disease progression in chronic lymphocytic leukemia.
Article in Oncotarget, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 46 citations in OpenAlex.
- MicroRNAs: Potential prognostic and theranostic biomarkers in chronic lymphocytic leukemia.EJHaem · 2024Review
- Role of microRNAs in Chronic Lymphocytic Leukemia.International journal of molecular sciences · 2023Review
- Inside the chronic lymphocytic leukemia cell: miRNA and chromosomal aberrations.Molecular medicine reports · 2022Article
- Small Non-Coding RNAs in Leukemia.Cancers · 2022Review
- Non-coding RNAs (miRNAs and lncRNAs) and their roles in lymphogenesis in all types of lymphomas and lymphoid malignancies.Oncology letters · 2021Review
- Enhanced Expression ofCancers · 2021Article
- Tumor Suppressors in Chronic Lymphocytic Leukemia: From Lost Partners to Active Targets.Cancers · 2020Review
- Serum Expression of Seven MicroRNAs in Chronic Lymphocytic Leukemia Patients.Journal of blood medicine · 2020Article
- MicroRNAs as Biomarkers of B-cell Lymphoma.Biomarker insights · 2018Review
- MicroRNA-181b is downregulated in non-small cell lung cancer and inhibits cell motility by directly targeting HMGB1.Oncology letters · 2016Article
- Clinical significance of microRNAs in chronic and acute human leukemia.Molecular cancer · 2016Review
- MicroRNAs in chronic lymphocytic leukemia: miRacle or miRage for prognosis and targeted therapies?Seminars in oncology · 2016Review
- Identification of miR-15b as a transformation-related factor in mantle cell lymphoma.International journal of oncology · 2016Article
- Roles of microRNA-146a and microRNA-181b in regulating the secretion of tumor necrosis factor-α and interleukin-1β in silicon dioxide-induced NR8383 rat macrophages.Molecular medicine reports · 2015Article
- MicroRNA-181b regulates ALX/FPR2 receptor expression and proresolution signaling in human macrophages.The Journal of biological chemistry · 2015Article
- Review
- MicroRNAs in Cancer Biology and Therapy: Current Status and Perspectives.Genes & diseases · 2014Article
- miR-34: from bench to bedside.Oncotarget · 2014Review
- Genetic subclonal complexity and miR125a-5p down-regulation identify a subset of patients with inferior outcome in low-risk CLL patients.Oncotarget · 2014Article
- Down-regulation of miR-181b promotes apoptosis by targeting CYLD in thyroid papillary cancer.International journal of clinical and experimental pathology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
Abstract
Over the past decades numerous markers of the tumor burden have been discovered in chronic lymphocytic leukemia (CLL). Among these, the microRNAs seem to have a promising role. The development and validation of miRNAs as biomarkers should have significant impact in improving early cancer detection and diagnosis, enhancing therapeutic success, and increasing the life expectancy of patients. We identified miR-181b as a biomarker for the progression of this disease from indolent to aggressive. For this study we used sequential samples from patients with either progressive or stable course of the illness. Here, we discuss more extensively this issue by adding novel findings and introducing a novel approach for monitoring CLL patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.